Evercore ISI Cuts Teradata (NYSE:TDC) Price Target to $32.00
Teradata (NYSE:TDC – Free Report) had its target price cut by Evercore ISI from $37.00 to $32.00 in a research report report ...
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $45.00 at Evercore ISI
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target hoisted by Evercore ISI from $33.00 to $45.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently ...
Evercore ISI's Mark Mahaney likes Meta, but says other names will give more upside
Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning ...
CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
Fintel on MSN20h
Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...
CRISPR Therapeutics stock rises following analyst upgrade
Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.
PG&E price target lowered to $15 from $20 at Evercore ISI
Evercore ISI analyst Michael Lonegan lowered the firm’s price target on PG&E to $15 from $20 and keeps an In Line rating on the shares. The ...